Extracorporeal Photopheresis - An Overview

被引:79
作者
Cho, Ara [1 ]
Jantschitsch, Christian [1 ]
Knobler, Robert [1 ]
机构
[1] Med Univ Wien, Dept Dermatol, Vienna, Austria
关键词
ECP; ultraviolet A; CTCL; GVHD; scleroderma; solid organ transplantation; VERSUS-HOST-DISEASE; T-CELL LYMPHOMA; HEART-TRANSPLANT REJECTION; SEVERE ATOPIC-DERMATITIS; BRONCHIOLITIS OBLITERANS SYNDROME; CONSENSUS DEVELOPMENT PROJECT; SYSTEMIC-SCLEROSIS; CLINICAL-TRIALS; DENDRITIC CELLS; CROHNS-DISEASE;
D O I
10.3389/fmed.2018.00236
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after receiving FDA approval for the palliative treatment of the Sezary Syndrome variant of cutaneous T-cell lymphoma (CTCL) in 1988. After the first positive experiences with CTCL, additional indications have been successfully explored including areas such as graft-vs.-host disease (GVHD), scleroderma, and solid organ transplantation. The mechanism of action is still not fully resolved, but important steps in understanding ECP in recent years have been very informative. Originally, the primary hypothesis stated that psoralen and ultraviolet A (UVA) in combination induce apoptosis in the treated immune cells. This view shifted in favor of dendritic cell initiation, modification of the cytokine profile and stimulation of several T-cell lineages, in particular regulatory T-cells. A number of ECP guidelines have been produced to optimize treatment regimens in the clinical context. In CTCL, enough evidence is available for the use of ECP as a first line treatment for Sezary Syndrome (SS), but also as a second line or rescue treatment in therapy-refractory forms of mycosis fungoides (MF). ECP in the treatment of acute and chronic GVHD has shown promising results as second line therapy in steroid-refractory presentations. In solid organ transplantation, ECP has been used to increase tissue tolerance and decrease infections with opportunistic pathogens, attributed to the use of high doses of immunosuppressive medication. Infection with cytomegalovirus (CMV) remains a limiting factor affecting survival in solid organ transplantation and the role of ECP will be discussed in this review. A trend toward prophylactic use of ECP can be observed and may further contribute to improve the outcome in many patients. To further deepen our knowledge of ECP and thus facilitate its use in patients that potentially benefit most from it, future prospective randomized trials are urgently needed in this rapidly growing field. The aim of this review is to (1) introduce the method, (2) give an overview where ECP has shown promising effects and has become an essential part of treatment protocols, and (3) to give recommendations on how to proceed in numerous indications.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Extracorporeal Photopheresis in Children with Chronic Graft-Versus-Host Disease
    Kozlov, Andrey
    Estrina, Maria
    Paina, Olesia
    Bykova, Tatiana
    Osipova, Anna
    Kozhokar, Polina
    Rakhmanova, Zhemal
    Solodova, Irina
    Morozova, Elena
    Alyansky, Alexander
    Kulagina, Irina
    Gevorgian, Asmik
    Dotsenko, Anna
    Moiseev, Ivan
    Chukhlovin, Alexey
    Kulagin, Alexander
    Bondarenko, Sergey
    Semenova, Elena
    Zubarovskaya, Ludmila
    PHARMACEUTICALS, 2021, 14 (08)
  • [42] Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells
    Ni, Ming
    Wang, Lei
    Ding, Yuntian
    Gong, Wenjie
    Wang, Sanmei
    Neuber, Brigitte
    Schubert, Maria-Luisa
    Sauer, Tim
    Huckelhoven-Krauss, Angela
    Luft, Thomas
    Hegenbart, Ute
    Schonland, Stefan
    Eckstein, Volker
    Wang, Jishi
    Kruger, William
    Muller-Tidow, Carsten
    Dreger, Peter
    Schmitt, Michael
    Schmitt, Anita
    CYTOTHERAPY, 2022, 24 (03) : 311 - 319
  • [43] Extracorporeal Photopheresis Promotes IL-1β Production
    Yakut, Erhan
    Jakobs, Christopher
    Peric, Adriana
    Michel, Gabriela
    Baal, Nelli
    Bein, Gregor
    Bruene, Bernhard
    Hornung, Veit
    Hackstein, Holger
    JOURNAL OF IMMUNOLOGY, 2015, 194 (06) : 2569 - 2577
  • [44] Racial differences in the use of extracorporeal photopheresis for mycosis fungoides
    Agi, Crystal
    Kuhn, Diane
    Chung, Jina
    Zampella, John
    Hinds, Ginette
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (03) : 266 - 268
  • [45] Extracorporeal Photopheresis in Solid Organ Transplantation (Lung Transplantation)
    Achenbach, Susanne
    Hackstein, Holger
    TRANSFUSIONSMEDIZIN, 2024, 14 (04) : 200 - 203
  • [46] Extracorporeal Photopheresis in Graft-versus-Host Disease
    Drexler, Beatrice
    Buser, Andreas
    Infanti, Laura
    Stehle, Gregor
    Halter, Joerg
    Holbro, Andreas
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2020, 47 (03) : 214 - 224
  • [47] Mode of action, indications and recommendations on extracorporeal photopheresis (ECP)
    Cho, Ara
    Paulitschke, Verena
    Knobler, Robert
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, : 1369 - 1380
  • [48] Extracorporeal photopheresis: From solid organs to face transplantation
    Hivelin, Mikael
    Siemionow, Maria
    Grimbert, Philippe
    Lantieri, Laurent
    TRANSPLANT IMMUNOLOGY, 2009, 21 (03) : 117 - 128
  • [49] Immune modulation with extracorporeal photopheresis in renal transplantation: proof of concept clinical outcomes and perspective
    Crepin, Thomas
    Lionet, Arnaud
    Augusto, Jean-Francois
    Hazzan, Marc
    Garrouste, Cyril
    Heng, Anne-Elisabeth
    Ducloux, Didier
    NEPHROLOGIE & THERAPEUTIQUE, 2023, 19 (06): : 521 - 531
  • [50] Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD
    Rieber, N.
    Wecker, I.
    Neri, D.
    Fuchs, K.
    Schaefer, I.
    Brand, A.
    Pfeiffer, M.
    Lang, P.
    Bethge, W.
    Amon, O.
    Handgretinger, R.
    Hartl, D.
    BONE MARROW TRANSPLANTATION, 2014, 49 (04) : 545 - 552